Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hansoh Signs $218 Million Agreement with NiKang for Oncology Asset

publication date: May 3, 2022

Shanghai Hansoh Pharma announced a $218 million agreement to acquire Greater China rights for a small molecule oncology candidate developed by NiKang Pharma of Delaware. NiKang is currently conducting a US Phase I/II dose escalation and expansion trial of NKT2152, a small molecule drug that inhibits HIF2α, in patients with clear cell renal cell carcinoma. Hansoh will pay $15 million upfront and up to $203 million in milestone payments, plus royalties. It’s the second partnership between the two companies: two years ago, Hansoh in-licensed greater China rights to a small molecule anti-viral candidate from NiKang in a $100 million deal. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues: